{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T05:26:41Z","timestamp":1730870801442,"version":"3.28.0"},"reference-count":18,"publisher":"Georg Thieme Verlag KG","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dtsch Med Wochenschr"],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:title>Was ist neu?<\/jats:title><jats:p>\n            Scores zur Risikoeinsch\u00e4tzung Die chronische Nierenerkrankung (CKD) ist eine h\u00e4ufige Komorbidit\u00e4t bei Vorhofflimmern, wobei der CHA2DS2-VASc-Score bei h\u00f6hergradiger CKD nicht validiert ist und bei Dialysepatienten nur einen geringen pr\u00e4diktiven Wert aufweist.<\/jats:p><jats:p>\n            Risikoreduktion Nach den aktuellen Empfehlungen der European Society of Cardiology (ESC) sind Nicht-Vitamin-K-antagonistische Orale Antikoagulanzien (NOAK) einer Vitamin-K-Hemmung vorzuziehen. Aufgrund der teilweisen renalen Elimination von NOAK ist die Dosis bei CKD anzupassen. Mehrere Studien deuten inzwischen auf ein akzeptables Sicherheitsprofil von NOAKs bei CKD hin, wobei gr\u00f6\u00dfere randomisierte Studien nach wie vor fehlen. Die Ergebnisse von prospektiven Studien mit einem Placebo-Behandlungsarm, d.h. ohne Antikoagulationstherapie, sind noch ausstehend.<\/jats:p><jats:p>\n            Vorhofohrverschluss bei Kontraindikationen Sollten Kontraindikationen f\u00fcr eine antithrombotische Therapie vorliegen, kann ein Vorhofohrverschluss diskutiert werden. Die Wirksamkeit und Sicherheit des Vorhofohrverschlusses muss jedoch noch besser evaluiert werden.<\/jats:p>","DOI":"10.1055\/a-2149-4290","type":"journal-article","created":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T22:43:13Z","timestamp":1716504193000},"page":"724-727","source":"Crossref","is-referenced-by-count":0,"title":["Vorhofflimmern \u2013 Was ist bei chronischer Nierenerkrankung und H\u00e4modialyse zu beachten?"],"prefix":"10.1055","volume":"149","author":[{"given":"Georg","family":"Schlieper","sequence":"additional","affiliation":[{"name":"Zentrum f\u00fcr Nieren-, Hochdruck- und Stoffwechselerkrankungen, Hannover"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2024,5,23]]},"reference":[{"issue":"05","key":"ref1","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC","volume":"42","author":"G Hindricks","year":"2021","journal-title":"Eur Heart J"},{"issue":"09","key":"ref2","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1136\/heartjnl-2013-305417","article-title":"The dialysis procedure as a trigger for atrial fibrillation: new insights in the development of atrial fibrillation in dialysis patients","volume":"100","author":"MS Buiten","year":"2014","journal-title":"Heart"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.jclinepi.2020.03.015","article-title":"A systematic review and external validation of stroke prediction models demonstrates poor performance in dialysis patients","volume":"123","author":"Y de Jong","year":"2020","journal-title":"J Clin Epidemiol"},{"issue":"09","key":"ref4","doi-asserted-by":"publisher","first-page":"100690","DOI":"10.1016\/j.xkme.2023.100690","article-title":"Atrial Fibrillation in Kidney Failure: Challenges in Risk Assessment and Anticoagulation Management","volume":"5","author":"MM Law","year":"2023","journal-title":"Kidney Med"},{"issue":"06","key":"ref5","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1160\/TH15-02-0154","article-title":"Stroke risk in atrial fibrillation: Do we anticoagulate CHADS2 or CHA2DS2-VASc \u22651, or higher?","volume":"113","author":"JB Olesen","year":"2015","journal-title":"Thromb Haemost"},{"issue":"12","key":"ref6","doi-asserted-by":"publisher","first-page":"857","DOI":"10.7326\/0003-4819-146-12-200706190-00007","article-title":"Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation","volume":"146","author":"RG Hart","year":"2007","journal-title":"Ann Intern Med"},{"issue":"01","key":"ref7","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1161\/CIR.0000000000001193","article-title":"2023 ACC\/AHA\/ACCP\/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"149","author":"JA Joglar","year":"2024","journal-title":"Circulation"},{"issue":"24","key":"ref8","doi-asserted-by":"publisher","first-page":"2314","DOI":"10.1093\/eurheartj\/ehy060","article-title":"Chronic kidney disease and arrhythmias: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference","volume":"39","author":"MP Turakhia","year":"2018","journal-title":"Eur Heart J"},{"issue":"09","key":"ref9","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1016\/j.amjmed.2019.04.013","article-title":"Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Severe Kidney Disease or Undergoing Hemodialysis","volume":"132","author":"CI Coleman","year":"2019","journal-title":"Am J Med"},{"issue":"15","key":"ref10","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1161\/CIRCULATIONAHA.118.035418","article-title":"Outcomes Associated With Apixaban Use in Patients With End-Stage Kidney Disease and Atrial Fibrillation in the United States [published correction appears in Circulation. 2018 Oct 9;138(15):e425]","volume":"138","author":"KC Siontis","year":"2018","journal-title":"Circulation"},{"issue":"05","key":"ref11","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1053\/j.ajkd.2022.03.007","article-title":"Apixaban Dosing Patterns Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation Receiving Dialysis: A Retrospective Cohort Study","volume":"80","author":"JB Wetmore","year":"2022","journal-title":"Am J Kidney Dis"},{"issue":"01","key":"ref12","doi-asserted-by":"publisher","first-page":"6123","DOI":"10.1038\/s41598-022-10164-5","article-title":"Real world data of anticoagulant treatment in non-valvular atrial fibrillation across renal function status","volume":"12","author":"JM Calderon","year":"2022","journal-title":"Sci Rep"},{"issue":"06","key":"ref13","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1681\/ASN.2020111566","article-title":"Safety and Efficacy of Vitamin K Antagonists versus Rivaroxaban in Hemodialysis Patients with Atrial Fibrillation: A Multicenter Randomized Controlled Trial","volume":"32","author":"AS De Vriese","year":"2021","journal-title":"J Am Soc Nephrol"},{"issue":"04","key":"ref14","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1161\/CIRCULATIONAHA.122.062779","article-title":"A Randomized Controlled Trial Comparing Apixaban With the Vitamin K Antagonist Phenprocoumon in Patients on Chronic Hemodialysis: The AXADIA-AFNET 8 Study","volume":"147","author":"H Reinecke","year":"2023","journal-title":"Circulation"},{"issue":"23","key":"ref15","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1161\/CIRCULATIONAHA.121.054990","article-title":"Apixaban for Patients With Atrial Fibrillation on Hemodialysis: A Multicenter Randomized Controlled Trial","volume":"146","author":"SD Pokorney","year":"2022","journal-title":"Circulation"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1261183","DOI":"10.3389\/fcvm.2023.1261183","article-title":"The safety and efficacy of direct oral anticoagulants among chronic kidney disease patients on dialysis with non-valvular atrial fibrillation: a meta-analysis","volume":"10","author":"JAL Mapili","year":"2023","journal-title":"Front Cardiovasc Med"},{"issue":"03","key":"ref17","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1002\/ccd.30559","article-title":"Left atrial appendage closure in end-stage renal disease and hemodialysis: Data from a German multicenter registry","volume":"101","author":"T Fink","year":"2023","journal-title":"Catheter Cardiovasc Interv"},{"issue":"07","key":"ref18","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1111\/pace.14537","article-title":"Left atrial appendage closure using WATCHMAN device in chronic kidney disease and end-stage renal disease patients","volume":"45","author":"S Jamal","year":"2022","journal-title":"Pacing Clin Electrophysiol"}],"container-title":["DMW - Deutsche Medizinische Wochenschrift"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2149-4290.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T12:46:44Z","timestamp":1730810804000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2149-4290"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,23]]},"references-count":18,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,5,23]]},"published-print":{"date-parts":[[2024,6]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2149-4290","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0012-0472","1439-4413"],"issn-type":[{"type":"print","value":"0012-0472"},{"type":"electronic","value":"1439-4413"}],"subject":[],"published":{"date-parts":[[2024,5,23]]}}}